PHF20 stabilizes β-Catenin in a WISP1/BGN-dependent manner. (A) The expression level of β-Catenin was analyzed by qPCR in PHF20 KO and control glioma cells. (B) Western blot analysis of β-Catenin in PHF20 KO and control glioma cells. (C) IHC staining of β-Catenin in xenografts. Scale bar, 50 μm. Control cells (non-specific sgRNA), KO cells (PHF20 sgRNA). (D) Western blot analysis of PHF20, WDR5, WISP1, BGN, and β-Catenin in PHF20 KO (PHF20 sgRNA + PHF20 Teton, without doxycycline), PHF20 Teton (PHF20 sgRNA + PHF20 Teton + control shRNA, with doxycycline), PHF20 Teton + WDR5 KD (PHF20 sgRNA + PHF20 Teton + WDR5 shRNA, with doxycycline), PHF20 Teton + WISP1 KD (PHF20 sgRNA + PHF20 Teton + WISP1 shRNA, with doxycycline), PHF20 Teton + BGN KD (PHF20 sgRNA + PHF20 Teton + BGN shRNA, with doxycycline), PHF20 Teton + (WISP1 + BGN) KD (PHF20 sgRNA + PHF20 Teton + WISP1 shRNA + BGN shRNA, with doxycycline), and control GBM cells (non-specific sgRNA). (E) Western blot analysis of WISP1, BGN, and β-Catenin in PHF20 KO (PHF20 sgRNA + PHF20 Teton, without doxycycline), PHF20 KO + WISP1 Teton (PHF20 sgRNA + WISP1 Teton, with doxycycline), PHF20 KO + BGN Teton (PHF20 sgRNA + BGN Teton, with doxycycline), PHF20 KO + (WISP1 + BGN) Teton (PHF20 sgRNA + WISP1 Teton + BGN Teton, with doxycycline), and control GBM cells (non-specific sgRNA). (F) The association between β-Catenin expression in GBM and the tumor-free survival time of selected patients was analyzed using Kaplan–Meier analysis with the TCGA dataset.